Head and Neck Cancer of Unknown Primary
Occult primary · Cervical metastasis of unknown primary · CUP of the head and neck · HPV-related unknown primary | ICD-10 C79.8 / C80 (metastatic cervical node, primary unidentified)
Head and neck cancer of unknown primary means a malignant cervical lymph node is found but no primary tumour can be seen after the initial examination. In North America and Northern Europe this presentation has become more common because small HPV-positive tonsil or base-of-tongue cancers hide in crypts. p16/HPV and EBV testing on the node aspirate usually points to the tissue of origin.
A painless neck lump in an adult is cancer until proven otherwise. The work-up aims to find a hidden primary in the tonsil, base of tongue, nasopharynx, hypopharynx, thyroid, salivary gland or skin. When HPV-driven oropharyngeal cancer is common — as in the US, UK and Scandinavia — an HPV-positive, cystic upper-neck node with no visible lesion is now a recognisable clinical entity rather than a mystery.
Finding the primary changes treatment: it can allow a smaller radiation field, transoral surgical resection and less long-term toxicity. Modern work-up therefore adds PET-CT, p16 and HPV/EBV testing, examination under anaesthesia, palatine tonsillectomy and transoral robotic base-of-tongue mucosectomy to the traditional endoscopic evaluation.
Where in the world is head and neck cancer of unknown primary common?
about 2–5% of head and neck squamous cell carcinoma presentations were estimated worldwide in 2022 (no separate global ASR — cases are coded to the metastatic site, not the hidden primary).
The proportion of unknown-primary cases that are HPV/p16-positive has risen sharply in high-income countries alongside the HPV-related oropharyngeal cancer epidemic.
| Region / country | What the data show |
|---|---|
| North America | Oropharyngeal cancer makes up 43.8% of the region’s lip/oral/pharyngeal burden and about 70% of US oropharyngeal cancers are HPV-positive — the main reason occult tonsil/base-of-tongue primaries are frequently encountered. |
| Northern Europe & UK | High HPV-attributable fractions (52–77%) produce the same pattern of small, node-positive, visually occult primaries in younger non-smokers. |
| South-East Asia & North Africa | Nasopharyngeal carcinoma is the hidden primary to exclude; plasma EBV DNA, nasopharyngoscopy and MRI of the nasopharynx are essential. |
| Australia & New Zealand | Both HPV-related oropharyngeal cancer and UV-related head and neck skin cancer are common, so scalp, ear and facial skin must be examined as possible primaries. |
| South Asia | Oral cavity and hypopharyngeal cancers dominate; careful oral and panendoscopic examination is needed to exclude a small mucosal primary. |
What are the risk factors?
- Persistent high-risk HPV-16 infection (HPV-related occult oropharyngeal primary)
- Tobacco and heavy alcohol use (HPV-negative mucosal primary)
- EBV infection in endemic regions (occult nasopharyngeal primary)
- Cumulative UV exposure and prior skin cancer (occult cutaneous primary)
- Male sex and age 40–65 for HPV-related disease
- Prior incomplete excision of a neck mass before proper work-up
What are the signs and symptoms?
- A painless, firm or cystic lump in the upper or mid neck, present for weeks
- No visible sore or lump in the mouth, throat or nose
- Normal-looking tonsils or an asymmetric tonsil on close inspection
- Occasionally unilateral ear pain, mild throat discomfort or a sensation of a lump in the throat
- Skin lesions on the scalp, ear or face that the patient has not mentioned
- Rarely, hoarseness, swallowing change or weight loss from a deeper primary
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Fine-needle aspiration (FNA) or core biopsy of the neck node — never an open excisional biopsy as the first step
- p16 immunohistochemistry and confirmatory HPV DNA/RNA testing on the node specimen; EBER/EBV testing when NPC is possible
- Complete head and neck examination including flexible nasopharyngolaryngoscopy, oral cavity, scalp, ear and skin
- Contrast CT and/or MRI of the neck; FDG PET-CT before or after examination under anaesthesia
- Examination under anaesthesia with panendoscopy, bilateral palatine tonsillectomy and/or TORS base-of-tongue mucosectomy
- Thyroid, salivary gland and cutaneous assessment when histology is not squamous cell carcinoma
When the primary remains occult, staging is based on nodal burden (number, size, laterality), p16/HPV or EBV status and distant metastasis. Under AJCC 8, p16-positive node-positive disease without an identified primary is generally managed along the HPV-mediated oropharyngeal pathway rather than as a generic metastatic cancer.
What are the treatment options?
- If a primary is found (often in the tonsil or tongue base): site-directed surgery or radiotherapy following the relevant site guideline
- If no primary is found: neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy, or definitive chemoradiotherapy to the neck and likely mucosal sites
- HPV/p16-positive disease may be treated with a more limited or de-escalated approach — only within defined protocols or clinical trials
- Adjuvant concurrent chemoradiotherapy for extranodal extension or positive margins
- Immunotherapy/chemotherapy for distant metastatic disease; structured skin, thyroid and nasopharyngeal surveillance at follow-up
- Avoid "diagnostic excision" of the node before imaging and FNA — it increases nodal recurrence and complicates later neck dissection
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
HPV/p16-positive unknown-primary disease has a markedly better prognosis than HPV-negative disease, reflecting the excellent outcomes of HPV-associated oropharyngeal cancer (about 85% five-year survival in published cohorts). Prognosis worsens with bulky N3 nodes, extranodal extension, supraclavicular nodes, EBV-positive nasopharyngeal origin or distant metastasis.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- HPV vaccination according to national schedules (most effective before exposure)
- Stop smoking and heavy alcohol use
- Sun protection and regular skin checks for scalp, ear and face
- Prompt FNA of any persistent adult neck lump rather than repeated antibiotics
- In NPC-endemic regions, consider plasma EBV DNA and nasopharyngoscopy as part of the work-up
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
A Chinese head and neck centre can repeat the FNA or review the cell block, perform p16/HPV and EBER testing, complete PET-CT and MRI staging, and carry out examination under anaesthesia with tonsillectomy or transoral tongue-base mucosectomy to look for the hidden primary before any treatment is started.
- Bring the original FNA slides/cell block, pathology report, CT/MRI/PET-CT on DICOM, and photographs of the neck mass.
- Ask that p16, HPV DNA/RNA and EBV (EBER) studies be performed or repeated before the tumour board decides the radiation field.
- Request a written statement of whether a primary was found, where, and how the treatment field was chosen.
- Do not allow an open excision of the node as the first procedure; ask for FNA or core biopsy instead.
Cost guidance: As an illustrative planning range, diagnostic work-up with PET-CT, endoscopy under anaesthesia and pathology review is commonly budgeted at ¥15,000–¥40,000 (about US$2,100–5,600); neck dissection with adjuvant radiotherapy ¥90,000–¥190,000. These are budgeting figures, not a quotation.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 13 questions about head and neck cancer of unknown primary
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
3 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
4 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Prognosis & follow-up
1 questionSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
1 questionWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is head and neck cancer of unknown primary?
Head and neck cancer of unknown primary means a malignant cervical lymph node is found but no primary tumour can be seen after the initial examination. In North America and Northern Europe this presentation has become more common because small HPV-positive tonsil or base-of-tongue cancers hide in crypts. p16/HPV and EBV testing on the node aspirate usually points to the tissue of origin.
Where in the world is head and neck cancer of unknown primary most common?
Head and Neck Cancer of Unknown Primary is not evenly distributed: the highest-burden regions are North America, Northern Europe & UK and South-East Asia & North Africa. In 2022 there were about 2–5% of head and neck squamous cell carcinoma presentations worldwide (no separate global ASR — cases are coded to the metastatic site, not the hidden primary), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for head and neck cancer of unknown primary?
The main recognised risk factors for head and neck cancer of unknown primary are persistent high-risk HPV-16 infection (HPV-related occult oropharyngeal primary), tobacco and heavy alcohol use (HPV-negative mucosal primary) and EBV infection in endemic regions (occult nasopharyngeal primary). Risks differ by region: North America has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of head and neck cancer of unknown primary?
The common early signs are a painless, firm or cystic lump in the upper or mid neck, present for weeks, no visible sore or lump in the mouth, throat or nose, normal-looking tonsils or an asymmetric tonsil on close inspection and occasionally unilateral ear pain, mild throat discomfort or a sensation of a lump in the throat. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is head and neck cancer of unknown primary diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for head and neck cancer of unknown primary?
Treatment is stage- and site-specific, and usually combines if a primary is found (often in the tonsil or tongue base): site-directed surgery or radiotherapy following the relevant site guideline, if no primary is found: neck dissection followed by risk-adapted radiotherapy or chemoradiotherapy, or definitive chemoradiotherapy to the neck and likely mucosal sites and HPV/p16-positive disease may be treated with a more limited or de-escalated approach — only within defined protocols or clinical trials. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for head and neck cancer of unknown primary?
HPV/p16-positive unknown-primary disease has a markedly better prognosis than HPV-negative disease, reflecting the excellent outcomes of HPV-associated oropharyngeal cancer (about 85% five-year survival in published cohorts). Prognosis worsens with bulky N3 nodes, extranodal extension, supraclavicular nodes, EBV-positive nasopharyngeal origin or distant metastasis.
Can head and neck cancer of unknown primary be prevented?
Many cases are preventable. The most useful steps for head and neck cancer of unknown primary are HPV vaccination according to national schedules (most effective before exposure), stop smoking and heavy alcohol use and sun protection and regular skin checks for scalp, ear and face. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
What is the first test for a persistent neck lump in an adult?
An ultrasound-guided fine-needle aspiration (FNA) or core biopsy, together with a complete head and neck endoscopic examination. An open excisional biopsy as the first step should be avoided: it can seed tumour cells, distort lymphatic drainage and make later neck dissection and radiotherapy more difficult.
Why can a cancer be too small to see but already spread to the neck?
The palatine tonsils and base of tongue are lined by crypt epithelium that is especially susceptible to HPV-16. A tumour only a few millimetres across can shed cells into lymphatic vessels very early, producing a large nodal metastasis while the primary remains invisible even on endoscopy and MRI.
How is a hidden primary tumour found?
After FNA, contrast CT/MRI and FDG PET-CT, the standard next step is examination under anaesthesia with directed biopsies, bilateral palatine tonsillectomy and, increasingly, transoral robotic (TORS) mucosectomy of the base of tongue. These procedures find a small primary in a substantial proportion of patients previously labelled "unknown".
What happens if no primary tumour is ever found?
Treatment still proceeds, usually with neck dissection followed by risk-adapted radiotherapy (with chemotherapy for extranodal extension or positive margins), or with definitive chemoradiotherapy covering the neck and the likely mucosal sites. HPV-positive disease may qualify for a more limited field within established protocols.
What does an unknown-primary work-up and treatment cost in China?
As a planning range, the diagnostic work-up (PET-CT, MRI, endoscopy under anaesthesia, pathology review and biomarker studies) is commonly budgeted at ¥15,000–¥40,000 (about US$2,100–5,600); neck dissection with adjuvant radiotherapy ¥90,000–¥190,000. These are budgeting figures, not a quotation.
Sources for this topic
- HPV & Oropharyngeal Cancer
- HPV Detection in Oropharyngeal Cancer: A Narrative Review
- NCCN Guidelines for Patients: Head and Neck Cancers
- Head and Neck Cancers (patient information)
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022
- Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities
Ask about head and neck cancer of unknown primary treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.